Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Conflict of interest disclosure in off-label oncology clinical trials.

Irwin B, Hirsch BR, Samsa GP, Abernethy AP.

J Oncol Pract. 2012 Sep;8(5):298-302. doi: 10.1200/JOP.2011.000523. Epub 2012 Jun 26.

2.

Why we need easy access to all data from all clinical trials and how to accomplish it.

Gøtzsche PC.

Trials. 2011 Nov 23;12:249. doi: 10.1186/1745-6215-12-249.

3.

Legislation for trial registration and data transparency.

Bian ZX, Wu TX.

Trials. 2010 May 26;11:64. doi: 10.1186/1745-6215-11-64.

4.

Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals.

Hirsch LJ.

Mayo Clin Proc. 2009 Sep;84(9):811-21. doi: 10.1016/S0025-6196(11)60491-6. No abstract available. Erratum in: Mayo Clin Proc. 2010 Jan;85(1):102.

5.

Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols.

Chan AW, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG.

BMJ. 2008 Dec 4;337:a2299. doi: 10.1136/bmj.a2299.

7.

An economic model of long-term use of celecoxib in patients with osteoarthritis.

Loyd M, Rublee D, Jacobs P.

BMC Gastroenterol. 2007 Jul 4;7:25.

8.

Life without COX 2 inhibitors.

Shaughnessy AF, Gordon AE.

BMJ. 2006 Jun 3;332(7553):1287-8. No abstract available.

9.

Inconsistencies in cardiovascular data from COX-2 inhibitor trials--is it a class effect?

Weatherall M, Aldington S, Caldwell B, Beasley R.

J R Soc Med. 2006 Jun;99(6):275-6. No abstract available.

10.

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R.

J R Soc Med. 2006 Mar;99(3):132-40. Review.

11.

JAMA's policy on industry sponsored studies.

Fontanarosa PB, DeAngelis CD.

BMJ. 2006 Jan 21;332(7534):177. No abstract available.

12.

Principles for evidence-based drug formulary policy.

Simon GE, Psaty BM, Hrachovec JB, Mora M.

J Gen Intern Med. 2005 Oct;20(10):964-8.

13.

Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1).

Krleza-Jerić K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C.

BMJ. 2005 Apr 23;330(7497):956-8. Review. No abstract available. Erratum in: BMJ. 2005 May 28;330(7502):1258.

14.

Coxibs and serious adverse cardiovascular events: a class-effect?

Yoong JK.

J R Soc Med. 2004 Dec;97(12):609. No abstract available.

15.

Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

Becker JC, Domschke W, Pohle T.

Br J Clin Pharmacol. 2004 Dec;58(6):587-600. Review.

16.

Transparency in drug regulation: mirage or oasis?

Lexchin J, Mintzes B.

CMAJ. 2004 Nov 23;171(11):1363-5. No abstract available.

18.

COX-2 inhibitors: a CLASS act or Just VIGORously promoted.

Malhotra S, Shafiq N, Pandhi P.

MedGenMed. 2004 Mar 23;6(1):6. Review.

19.
Items per page

Supplemental Content

Write to the Help Desk